Sunday, 09 August 2020

Novavax receives $60m from DOD to secure 10 million COVID-19 vaccine doses

07 June 2020 | News

Novavax will collaborate with U.S.-based CDMOs to scale up production and manufacture of the Matrix-M adjuvant and component of the vaccine

image courtesy: freepik

image courtesy: freepik

Novavax commenced Phase I clinical trial for their COVID-19 vaccine "NVX-CoV2373" a stable prefusion protein antigen made using its proprietary nanoparticle technology, including its proprietary Matrix-M™ adjuvant in Australia. The U.S.-based company recently secured a contract with the U.S. Department of Defense (DoD) or the manufacturing of the COVID-19 vaccine target.

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CRBND-EB), along with funding by the Defense Health Program agreed to fund up to $60 million to support Novavax in its production of several components of the vaccine to be produced in America. The parties declared a targeted delivery in 2020 of 10 million doses of NVX-CoV2373 for DoD that could be used in Phase II/III clinical trials or under an Emergency Use Authorization (EUA) if approved by the U.S. Food and Drug Administration.

Novavax will work with a U.S.-based biologics contract development manufacturing organization (CDMO) to manufacture the antigen component of NVX-CoV2373 for at least 10 million doses of vaccine. 

Novavax recently initiated the development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2 Phase 1 clinical trial results expected in July of 2020. vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls